Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024

Company Overview - Alvotech is a biotech company focused on the development and manufacture of biosimilar medicines for patients worldwide [2] - The company aims to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services [2] - Alvotech's current pipeline includes eight disclosed biosimilar candidates targeting autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer [2] Strategic Partnerships - Alvotech has formed a network of strategic commercial partnerships to enhance its global reach and leverage local expertise [2] - Key commercial partners include Teva Pharmaceuticals, STADA Arzneimittel AG, Fuji Pharma Co., Ltd, and several others across various regions including the US, Europe, Japan, China, and parts of South America, Africa, and the Middle East [2] - Each partnership covers unique products and territories, allowing Alvotech to expand its market presence [2] Market Update - Alvotech will host an audio call for a market update on April 3, 2024, at 12:15 pm GMT / 08:15 am EDT [1] - The update will be provided by Anil Okay, Chief Commercial Officer, and will be accessible via the company's investor website [1] - The webcast will be archived and available for replay for 90 days after the event [1]